Researcher (Yanagita-G)
1, Establishment of a kidney disease model with human iPS cell-derived organoids
Chronic kidney disease (CKD) affects approximately 13 million people in Japan, which increases the risk of cardiovascular disease, end-stage renal disease, and mortality. On the other hand, there is no effective treatment.
Over the past decade, significant advances have been made in understanding the pathophysiology of CKD, mainly through the study of rodent models. However, the problem with rodent models is that they do not adequately recapitulate the morphological and genetic characteristics of human kidney diseases. Therefore, we would like to understand the pathogenesis of kidney disease by using human iPS cell-derived organoids to recapitulate human kidney disease and further analyze it at a single-cell level.
2. Elucidate the mechanism of the DoHAD theory
Low birth weight infants are more likely to develop lifestyle-related diseases such as CKD in adulthood. The phenomenon that the onset of lifestyle-related diseases is influenced by the intrauterine environment are called the DoHAD (Developmental Origins of Health and Disease) theory. We try to elucidate the DoHAD theory using PIC (Photo Isolation Chemistry)-RNAseq, a technique that can detect gene expression at the single-cell level.
2007-2013 Bachelor of Medicine, Kyoto University, Kyoto, Japan.
2013-2015 Resident, Kansai Electric Power Hospital, Osaka, Japan.
2015-2017 Fellows in Nephrology, Kansai Electric Power Hospital, Osaka, Japan.
2017-2018 Fellows in Nephrology, Toranomon Hospital Kajigaya, Kanagawa, Japan.
2018-2022 PhD in Nephrology, Graduate school of Medicine, Kyoto University, Kyoto, Japan.
1. Sato Y, Oguchi A, Fukushima Y, Masuda K, Toriu N, Taniguchi K, Yoshikawa T, Cui X, Kondo M, Hosoi T, Komidori S, Shimizu Y, Fujita H, Jiang L, Kong Y, Yamanashi T, Seita J, Yamamoto T, Toyokuni S, Hamazaki Y, Hattori M, Yoshikai Y, Boor P, Floege J, Kawamoto H, Murakawa Y, Minato N, Yanagita M: CD153-CD30 signaling promotes age-dependent tertiary lymphoid tissue expansion and kidney injury. J Clin Invest 2021.
2. Toriu N, Sumida K, Mizuno H, Hasegawa E, Suwabe T, Kawada M, et al. Long-term outcome of biopsy-proven cholesterol crystal embolism. Clinical and experimental nephrology. 2019;23(10):1181-7.
3. Toriu N, Sumida K, Oguro M, Oshima Y, Mizuno H, Hasegawa E, et al. Increase of 1,25 dihydroxyvitamin D in sarcoidosis patients with renal dysfunction. Clinical and experimental nephrology. 2019;23(10):1202-10.
4. Toriu N, Sawa N, Hiramatsu R, Mizuno H, Ikuma D, Sekine A, et al. Regression of renal amyloid deposits by VAD therapy plus autologous stem cell transplantation in a patient with primary AL amyloidosis. CEN Case Rep. 2020;9(1):6-10.
5. Toriu N, Ueno T, Mizuno H, Sekine A, Hayami N, Hiramatsu R, et al. Brown tumor diagnosed three years after parathyroidectomy in a patient with nail-patella syndrome: A case report. Bone Rep. 2019;10:100187.
6. Toriu N, Sekine A, Mizuno H, Hasegawa E, Yamanouchi M, Hiramatsu R, et al. Renal-Limited Thrombotic Microangiopathy due to Bevacizumab Therapy for Metastatic Colorectal Cancer: A Case Report. Case reports in oncology. 2019;12(2):391-400.
7. Toriu N, Yamanouchi M, Hiramatsu R, Hayami N, Hoshino J, Sekine A, et al. Preservation of renal function by intensive glycemic control. Endocrinol Diabetes Metab Case Rep. 2018;2018.
8. Toriu N, Yamanouchi M, Hiramatsu R, Hayami N, Hoshino J, Sekine A, et al. Tocilizumab prevents renal function of a patient with diabetic kidney disease: case report. Modern Rheumatology Case Reports. 2018;3(1):53-6.
9. Toriu N, Mizuno H, Sawa N, Sumida K, Suwabe T, Hayami N, et al. Everolimus Reduces the Size of Tuberous Sclerosis Complex-Related Huge Renal Angiomyolipomas Exceeding 20 cm in the Longest Diameter. Case reports in oncology. 2018;11(2):258-67.
10. Toriu N, Hoshino J, Kobori S, Watanabe S, Oguro M, Oshima Y, et al. Transcatheter Arterial Embolization Therapy for Huge Renal Cysts: Two Case Reports. Case Rep Nephrol Dial. 2018;8(1):82-9.
Excellence in research award (ASHBi Retreat 2022)
Apr. 1, 2022